- Home
- RMM vs JSPR Comparison
RMM vs JSPR Comparison
Compare RMM & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.71
Company Overview
Basic Information| Metric | RMM | JSPR |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 49.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMM | JSPR |
|---|---|---|
| Price | $13.74 | $1.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $25.60 |
| AVG Volume (30 Days) | 66.5K | ★ 3.8M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.32 | $1.39 |
| 52 Week High | $16.10 | $23.11 |
Technical Indicators
Market Signals| Indicator | RMM | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 44.63 |
| Support Level | $13.84 | $1.61 |
| Resistance Level | $14.03 | $1.93 |
| Average True Range (ATR) | 0.14 | 0.21 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 0.47 | 31.07 |
Price Performance
Historical Comparison RMM
JSPR
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.